# Clinical Trials Data EGFR - Document 63

# Prognostic Relevance of Biological Subtype in Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT02063906

"eligibilityCriteria": "Inclusion Criteria:\n\n\* patients who received curative surgery\n\* stage I-III breast cancer\n\* between January 2004 and September 2008\n\* had available immunohistochemistry profiles.\n\nexclusion Criteria:\n\n\* age \\<18 years old\n\* microinvasive carcinoma of breast",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients who received curative surgery for stage I-III breast cancer between January 2004 and September 2008 and had available immunohistochemistry profiles.",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the presence of an EGFR gene mutation is not explicitly mentioned as a criterion for either inclusion or exclusion. The main criteria that determine eligibility are related to:  
  
1. The patient having undergone curative surgery.  
2. The stage of breast cancer being I-III.  
3. The timeframe of diagnosis or treatment (between January 2004 and September 2008).  
4. Availability of immunohistochemistry profiles.  
5. The patient being female and aged 18 or older.  
6. Exclusion for microinvasive carcinoma of the breast.  
  
Unless there is additional information elsewhere in the trial protocol that specifies exclusion based on EGFR gene mutation or related molecular characteristics, a patient with an EGFR gene mutation could potentially be eligible for this trial. However, it would be best to confirm with the study coordinators or protocol details to ensure full understanding and compliance with all trial requirements.